Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Assets (2016 - 2025)

Coherus Oncology's Other Non-Current Assets history spans 13 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 90.84% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 90.84%, while the annual FY2025 figure was $4.1 million, 90.84% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $4.1 million at Coherus Oncology, down from $4.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $44.2 million in Q4 2024 and bottomed at $4.1 million in Q4 2025.
  • The 5-year median for Other Non-Current Assets is $8.9 million (2022), against an average of $10.0 million.
  • The largest annual shift saw Other Non-Current Assets surged 2341.82% in 2021 before it tumbled 90.84% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $10.0 million in 2021, then dropped by 13.54% to $8.7 million in 2022, then grew by 11.74% to $9.7 million in 2023, then skyrocketed by 356.77% to $44.2 million in 2024, then crashed by 90.84% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Non-Current Assets are $4.1 million (Q4 2025), $4.4 million (Q3 2025), and $5.0 million (Q2 2025).